联合鳖甲煎丸治疗非酒精性脂肪性肝病肝纤维化的疗效观察  

Effect observation of Biejiajian pill in the treatment of nonalcoholic fatty liver disease

作　　者：姜挺[1] 郑丹[1] 李晖[1] 余娇[1] 吴杰[1] 

机构地区：[1]武汉市中心医院消化内科,武汉430014

出　　处：《世界临床药物》2015年第10期690-692,701,共4页World Clinical Drug

摘　　要：目的观察联合鳖甲煎丸治疗对于非酒精性脂肪性肝病(NAFLD)肝纤维化的疗效。方法 263例NAFLD肝纤维化患者随机分为治疗组(n=131)和对照组(n=132),两组均常规给予护肝治疗,治疗组加用鳖甲煎丸治疗,疗程为24周,以患者肝脏生化、血脂、肝纤维化指标及肝脏硬度情况变化,评价肝纤维化改善疗效。结果与对照组比较,治疗组治疗后肝功能(除γ-GT)、血脂、肝纤维化以及肝脏硬度各项指标均显著降低(P<0.05)。结论联合应用鳖甲煎丸治疗,对NAFLD所致的肝纤维化具有良好的改善作用。Objective To observe the clinical efficacy of Biejiajian pill in the treatment of nonalcoholic fatty liver disease（NAFLD）. Methods A total of 263 cases of hepatic fi brosis in NAFLD patients were randomly divided into treatment group（131 cases） and control group（132 cases）. Both two groups were given conventional liver protective therapy, and the treatment group was given additional Biejiajian pill. The treatment was performed for 24 weeks. The liver function, serum lipid levels, hepatic fi brosis markers and liver hardness change were observed. Results Compared with the control group, the liver function（except γ-GT）, serum lipid levels, hepatic fi brosis and liver stiffness index of treatment group were decreased signifi cantly（P 〈0.05）. Conclusion The combined therapy with Biejiajian pill can relieve the clinical symptoms, improve liver function and liver stiffness and reduce hepatic fi brosis in NAFLD patients.

关 键 词：鳖甲煎丸 非酒精性脂肪性肝病 肝纤维化 

分 类 号：R575.2[医药卫生—消化系统] R932[医药卫生—内科学]